Education
About Us
Working with TipRanks
Follow Us
Terns Pharmaceuticals (TERN)
NASDAQ:TERN
TERN Analyst Ratings
Strong Buy
6 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
TERN Stock 12 Month Forecast
Average Price Target
$14.74
▲(92.93% Upside)
| Highest Price Target$20.00 | Average Price Target$14.74 | Lowest Price Target$7.44 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
William Blair
―
Hold
―
Reiterated
09/26/25
Mizuho Securities
$14
Buy
83.25%
Upside
Reiterated
09/19/25
Barclays
$15
Buy
96.34%
Upside
Initiated
09/16/25
UBS
$17
Buy
122.51%
Upside
Reiterated
09/15/25
Anticipated Data Updates and Underappreciated Catalysts Drive Buy Rating for Terns PharmaceuticalsColor from TERN mgmt at our fireside chat - we think obesity and CML data updates in early 4Q/4Q respectively are underappreciated catalysts We hosted a fireside chat with TERN mgmt (Amy Burroughs, CEO, Emil Kuriakose, CMO, and Andrew Gengos, CFO) ahead of two major readouts for TERN later this year - Ph2 topdata for TERN-601 (oral GLP-1) in obesity in early 4Q, and a data update from the Ph1 trial of TERN-701 (allosteric BCR-ABL) in chronic myeloid leukemia (CML) in 4Q. We think CML is a key focus for the stock as the company's main focus going forward (looking to partner in obesity).
H.C. Wainwright
$7.44
Hold
-2.62%
Downside
Initiated
09/04/25
Oppenheimer
$20
Buy
161.78%
Upside
Reiterated
09/04/25
TD Cowen
―
Buy
―
Reiterated
08/05/25
1:30 AM TERNS PHARMACEUTICALS (NASDAQ: TERN) Buy (1) ESG Target: NA 2Q25: PH1 CML '701 DOSE EXPANSION & PH2 '601 OBESITY DATA BOTH DUE IN 4Q25 THE TD COWEN INSIGHT The '701 Ph1 CARDINAL Part 2 dose expansion in CML is enrolling. Data from a larger pt cohort w/ longer tx duration and readthrough to the 6-mo MMR approval endpoint is due 4Q25, along with add'l Part 1 data. The '601 Ph2 FALCON dose-finding obesity trial is enrolling with data due early 4Q25. The 1º EP is % change from BL in body weight vs PBO at 12wks. Cash of $315M gives runway to 2028E.
Citizens JMP
$20
Buy
161.78%
Upside
Reiterated
06/17/25
BMO Capital
$15
Buy
96.34%
Upside
Reiterated
05/13/25
J.P. Morgan
$14
Hold
83.25%
Upside
Reiterated
05/09/25
Westpark Capital
$7.5
Hold
-1.83%
Downside
Reiterated
12/04/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
William Blair
―
Hold
―
Reiterated
09/26/25
Mizuho Securities
$14
Buy
83.25%
Upside
Reiterated
09/19/25
Barclays
$15
Buy
96.34%
Upside
Initiated
09/16/25
UBS
$17
Buy
122.51%
Upside
Reiterated
09/15/25
Anticipated Data Updates and Underappreciated Catalysts Drive Buy Rating for Terns PharmaceuticalsColor from TERN mgmt at our fireside chat - we think obesity and CML data updates in early 4Q/4Q respectively are underappreciated catalysts We hosted a fireside chat with TERN mgmt (Amy Burroughs, CEO, Emil Kuriakose, CMO, and Andrew Gengos, CFO) ahead of two major readouts for TERN later this year - Ph2 topdata for TERN-601 (oral GLP-1) in obesity in early 4Q, and a data update from the Ph1 trial of TERN-701 (allosteric BCR-ABL) in chronic myeloid leukemia (CML) in 4Q. We think CML is a key focus for the stock as the company's main focus going forward (looking to partner in obesity).
H.C. Wainwright
$7.44
Hold
-2.62%
Downside
Initiated
09/04/25
Oppenheimer
$20
Buy
161.78%
Upside
Reiterated
09/04/25
TD Cowen
―
Buy
―
Reiterated
08/05/25
1:30 AM TERNS PHARMACEUTICALS (NASDAQ: TERN) Buy (1) ESG Target: NA 2Q25: PH1 CML '701 DOSE EXPANSION & PH2 '601 OBESITY DATA BOTH DUE IN 4Q25 THE TD COWEN INSIGHT The '701 Ph1 CARDINAL Part 2 dose expansion in CML is enrolling. Data from a larger pt cohort w/ longer tx duration and readthrough to the 6-mo MMR approval endpoint is due 4Q25, along with add'l Part 1 data. The '601 Ph2 FALCON dose-finding obesity trial is enrolling with data due early 4Q25. The 1º EP is % change from BL in body weight vs PBO at 12wks. Cash of $315M gives runway to 2028E.
Citizens JMP
$20
Buy
161.78%
Upside
Reiterated
06/17/25
BMO Capital
$15
Buy
96.34%
Upside
Reiterated
05/13/25
J.P. Morgan
$14
Hold
83.25%
Upside
Reiterated
05/09/25
Westpark Capital
$7.5
Hold
-1.83%
Downside
Reiterated
12/04/24
Best Analysts Covering Terns Pharmaceuticals
1 Month
xxx
Success Rate
8/13 ratings generated profit
Average Return
+6.75%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 61.54% of your transactions generating a profit, with an average return of +6.75% per trade.
3 Months
xxx
Success Rate
8/13 ratings generated profit
Average Return
+13.18%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +13.18% per trade.
1 Year
Success Rate
11/20 ratings generated profit
Average Return
+16.00%
reiterated a buy rating 3 months ago
Copying Silvan Tuerkcan's trades and holding each position for 1 Year would result in 55.00% of your transactions generating a profit, with an average return of +16.00% per trade.
2 Years
xxx
Success Rate
8/10 ratings generated profit
Average Return
+15.56%
initiated a xxx
rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +15.56% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
TERN Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
7
6
5
5
10
Buy
1
0
0
1
1
Hold
5
3
2
1
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
9
7
7
15
Each month's total comprises the sum of three months' worth of ratings.
TERN Financial Forecast
TERN Stock Forecast FAQ
What is TERN’s average 12-month price target, according to analysts?
Based on analyst ratings, Terns Pharmaceuticals’s 12-month average price target is 14.74.
What is TERN’s upside potential, based on the analysts’ average price target?
Terns Pharmaceuticals has 92.93% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TERN a Buy, Sell or Hold?
Terns Pharmaceuticals has a consensus rating of Strong Buy which is based on 6 buy ratings, 2 hold ratings and 0 sell ratings.
What is Terns Pharmaceuticals’s price target?
The average price target for Terns Pharmaceuticals is 14.74. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $7.44. The average price target represents 92.93% Increase from the current price of $7.64.
The highest analyst price target is $20.00 ,the lowest forecast is $7.44. The average price target represents 92.93% Increase from the current price of $7.64.
What do analysts say about Terns Pharmaceuticals?
Terns Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of TERN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.